BioCentury
ARTICLE | Clinical News

AZ's Imfinzi/tremelimumab combo misses again, this time in another NSCLC

August 21, 2019 5:51 PM UTC

AstraZeneca announced Wednesday that its Imfinzi durvalumab/tremelimumab combination failed to show a survival benefit in first-line non-small cell lung cancer. While the miss marks an end to AZ's recent spate of clinical successes, investors appeared undaunted by the miss, continuing to push the stock up to 52-week highs.

In the Phase III NEPTUNE trial of Imfinzi plus tremelimumab, the combination did not meet the primary endpoint of a survival benefit over standard of care chemotherapy in patients with first-line stage IV NSCLC who have high tumor mutational burden (TMB). High TMB was defined as having 20 mutations or more per megabase...

BCIQ Company Profiles

AstraZeneca plc